A phase 1b, open-label, dose-escalation trial of the delta-like ligand 3 (dll3)/cd3 igg-like t cell engager, bi 764532, in patients with dll3-positive gliomaMartin van den Bent,Patrick Roth,Ghazaleh Tabatabai,Michael C. Burger,Maria Martinez-Garcia,Louisa von Baumgarten,Richard Greil,Matus Studeny, Monika Simetzberger,Meiruo LiuNEURO-ONCOLOGY(2023)引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要